USPTO serial 88617127
Reviewed by CopyMark Law Group
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Plus Government fees of $975
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Maury M. Tepper, III
Maury M. Tepper, III Tepper & Eyster, PLLC3724 Benson DriveRaleigh, NC 27609United States| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Antibodies for scientific purposes and not for medical or veterinary use; Monoclonal antibodies for diagnostic use and not for medical or veterinary use; Biochemicals, namely, monoclonal antibodies for scientific or research use; Tagged antibodies for scientific and laboratory use; immunological antibodies not for medical use; Reagents for use in the development of monoclonal antibodies not for medical or veterinary purposes; biological and biotechnological products used in industry and science, namely, antibodies and fragments of antibodies for use in the manufacture of pharmaceutical preparations; biological preparations for laboratories, for diagnostics, and for analysis and environmental analysis, other than for medical or veterinary use | ACTIVE | — |
| 005 | Pharmaceuticals and pharmaceutical preparations for human and veterinary use for the treatment and prevention of metabolic disorders, infectious diseases, cancer, inflammatory diseases, autoimmune diseases, Alzheimer, sepsis, and restenosis; diagnostic antibodies for medical purposes; biological substances for human medical diagnostics and analysis for the treatment of metabolic disorders, infectious diseases, cancer, inflammatory diseases, autoimmune diseases, Alzheimer, sepsis, and restenosis; medical diagnostic reagents; clinical medical reagents; Biological preparations for medical and veterinary purposes for the treatment of metabolic disorders, infectious diseases, cancer, inflammatory diseases, autoimmune diseases, Alzheimer, sepsis, and restenosis; biological preparations for medical and veterinary purposes, namely, antibodies sold as a component ingredient of pharmaceuticals | ACTIVE | — |
| 042 | Research and development in the pharmaceutical and biotechnology fields; research and development of vaccines and medicines; scientific and technological services, namely, scientific research, analysis, and testing services in the fields of analytical chemistry, biochemistry, medicinal chemistry, drug development, biotechnology, microbiology and molecular biology; biological research; clinical research in connection with the treatment and prevention of metabolic disorders, infectious diseases, cancer, inflammatory diseases, autoimmune diseases, Alzheimer, sepsis, and restenosis; medical research; chemical and biochemical analysis services; laboratory research in the fields of analytical chemistry, biochemistry, medicinal chemistry, drug development, biotechnology, microbiology and molecular biology; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; providing medical and scientific research information in the field of pharmaceuticals; research and development services in the field of antibodies | ACTIVE | — |
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 22, 2025 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Mar 21, 2025 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Mar 21, 2025 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Mar 21, 2025 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 21, 2025 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Mar 21, 2025 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Mar 21, 2025 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Sep 22, 2020 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jul 7, 2020 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jul 7, 2020 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jun 17, 2020 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jun 4, 2020 | FIXD | ELECTRONIC RECORD REVIEW COMPLETE | — |
| May 29, 2020 | ERRR | ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED | — |
| May 28, 2020 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 27, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 27, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 25, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 18, 2019 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 18, 2019 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 18, 2019 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 15, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 22, 2019 | AMPX | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED | — |
| Nov 21, 2019 | ALIE | ASSIGNED TO LIE | — |
| Nov 17, 2019 | PARI | TEAS VOLUNTARY AMENDMENT RECEIVED | — |
| Sep 23, 2019 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Sep 18, 2019 | NWAP | NEW APPLICATION ENTERED | — |